Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in CRSP.

← Back to Free Index

CRSP

Analysis as of: 2026-10-21

CRISPR Therapeutics AG

CRISPR Therapeutics develops gene-edited medicines across hematology, cardiometabolic disease, autoimmune disease and oncology, and shares CASGEVY economics with Vertex.

biotech healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Approved proof, but platform proof still pending

The case is not that every program wins. The case is that first-product credibility, time-rich funding and one clean wholly owned franchise can unlock a much larger business, while partner-controlled commercialization and regulatory gates keep the upside from becoming extreme.

Analysis

Thesis

CRISPR Therapeutics already has first-product credibility and ample time to fund multiple shots on goal; if CASGEVY keeps ramping and just one wholly owned cardiometabolic or autoimmune program becomes commercially real by 2031, the stock can re-rate from cash-backed optionality to a multi-franchise gene-editing platform.

Last Economy Alignment

AI helps edit design, target selection and portfolio learning, but the binding constraints are still biology, regulation, treatment sites and manufacturing.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.4x (from 5 most recent analyses)

Reasoning

The upside case does not require every program to win. A steady CASGEVY economic stream, one credible liver-directed in vivo franchise, and usable autoimmune read-through would likely shift investor framing from a science option to a repeatable multi-asset company. Shared economics, access friction and early-stage proof keep the outcome in fast-growth territory rather than hypergrowth.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is proof conversion, not survival. The balance sheet buys time, but the stock still needs broader platform validation beyond CASGEVY and enough direct economic capture from wholly owned assets to avoid staying a partner-mediated, cash-burning optionality story.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

On October 19, 2026, the CFO role turned over; that is a governance watch item, but it does not change the asset base or core thesis.
No new clinical efficacy data arrived in the last 10 days, so the near-term setup is still dominated by November CTX310 and zugo-cel disclosures.
Timing uncertainty has narrowed because the next major data windows are now explicit, but outcome uncertainty remains high and binary.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.33

They control valuable gene-editing know-how, delivery tools and some manufacturing, so AI can help them design and iterate faster. But this is still a biology-and-regulation business, and partner dependence plus treatment-site bottlenecks keep the score moderate rather than elite.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$85.63

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research